- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: EPA and Drinking Water; Teens Seek Vaccines; Companies Cut Praluent Price
The Environmental Protection Agency (EPA) is expected to make a decision soon regarding stricter regulations of polyfluoroalkyl compounds, or PFAS, which are chemicals in coatings meant to protect consumer goods from stains, water, and corrosion that have been found in drinking water; teenagers are turning to Reddit and other sites to figure out how to get vaccinated if their parents subscribe to antivaccine beliefs; Regeneron and Sanofi announced they are cutting the price of its proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab (Praluent).
Decision From EPA Expected Soon on Chemical Regulations Affecting Health
The Environmental Protection Agency (EPA) is expected to make a decision soon regarding stricter regulations of polyfluoroalkyl compounds, or PFAS, which are chemicals in coatings meant to protect consumer goods from stains, water, and corrosion, The Associated Press reported. Increasing numbers of states have found them seeping into water supplies; studies have indicated links between the chemicals and excessive cholesterol levels, ulcerative colitis, thyroid disease, testicular and kidney cancer, problems in pregnancies, low birth weight, and liver problems.
Teens From Homes With Antivaccine Beliefs Turning to Internet to Figure Out How to Get Vaccinated
Teenagers are turning to Reddit and other sites to figure out how to get vaccinated if their parents subscribe to antivaccine beliefs, The Washington Post reported. The paper detailed the pursuit of an Ohio teen who started to get his vaccinations done last fall, but the 18-year-old is afraid for his younger siblings.
Regeneron, Sanofi Cutting Price of Praluent by 60%
Regeneron and Sanofi announced they are cutting the price of its proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab (Praluent) by 60% in the United States. The companies said that the new list price will be $5850 annually in early March for both the 75 mg and 150 mg doses.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More
